HC Wainwright Estimates Annexon’s Q3 Earnings (NASDAQ:ANNX)

Annexon, Inc. (NASDAQ:ANNX) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Annexon in a research report issued on Thursday, August 13th. HC Wainwright analyst A. Ghosh now expects that the company will post earnings of ($0.27) per share for the quarter, down from their previous forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Annexon’s FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at $0.03 EPS and FY2030 earnings at $0.45 EPS.

A number of other brokerages have also issued reports on ANNX. Citigroup initiated coverage on shares of Annexon in a report on Tuesday, July 21st. They set a “market underperform” rating for the company. The Goldman Sachs Group started coverage on shares of Annexon in a report on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 target price on the stock. Needham & Company LLC upped their target price on shares of Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen cut shares of Annexon from a “sell” rating to a “strong sell” rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research note on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $15.33.

Annexon Trading Up 2.9%

NASDAQ ANNX opened at $5.28 on Monday. The stock’s 50 day moving average is $5.35 and its 200 day moving average is $5.49. Annexon has a 12 month low of $2.03 and a 12 month high of $7.18. The stock has a market cap of $1.00 billion, a PE ratio of -4.55 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04).

Institutional Trading of Annexon

Large investors have recently added to or reduced their stakes in the company. CIBC Bancorp USA Inc. bought a new position in shares of Annexon during the 3rd quarter valued at approximately $31,000. Engineers Gate Manager LP purchased a new position in shares of Annexon in the second quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. increased its position in Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after purchasing an additional 2,785 shares during the last quarter. Landscape Capital Management L.L.C. bought a new stake in Annexon in the fourth quarter worth $50,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Annexon during the fourth quarter valued at $52,000.

Insider Buying and Selling

In other news, Director Muneer A. Satter purchased 613,497 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was bought at an average cost of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the purchase, the director owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.31% of the company’s stock.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.